Last reviewed · How we verify
conventional dose epinephrine
At a glance
| Generic name | conventional dose epinephrine |
|---|---|
| Sponsor | Seoul National University Hospital |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Polycystic Ovary Syndrome in Type 1 Diabetes
- Early Adalimumab Induction for Immune Checkpoint Inhibitor Associated Inflammatory Arthritis (PHASE2)
- Comparison of Systemic Opioid (Morphine) and Pre-Incision Bilateral Scalp Nerve Block for Pain Management in Craniotomy Patients (PHASE4)
- Platform of Randomized Adaptive Clinical Trials in Critical Illness (NA)
- Molecular and Clinical Risk-Directed Therapy for Infants and Young Children With Newly Diagnosed Medulloblastoma (PHASE2)
- Effects of Telitacicept vs Cyclophosphamide on Lupus Related Interstitial Lung Disease (PHASE4)
- A Study of Gene Therapy for Classic Congenital Adrenal Hyperplasia (CAH) (PHASE1, PHASE2)
- Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1 (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- conventional dose epinephrine CI brief — competitive landscape report
- conventional dose epinephrine updates RSS · CI watch RSS
- Seoul National University Hospital portfolio CI